Task: gap030 | Last Updated: 2026-03-15 | Kind: gap-analysis | Total Gaps Identified: 15
Knowledge Gap: How should disease-modifying therapies be sequenced and combined to achieve optimal outcomes in neurodegenerative diseases?
This page explores the critical question of therapy sequencing and combination strategies for neurodegenerative diseases, examining sequential vs simultaneous approaches, biomarker-guided selection, mechanisms of synergy, and lessons from oncology.
Neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) represent a growing therapeutic challenge. The approval of disease-modifying therapies (DMTs) such as lecanemab and donanemab for early Alzheimer's disease has introduced new complexities in treatment optimization. Unlike single-target interventions, combination and sequencing strategies may offer superior efficacy by targeting multiple pathological mechanisms simultaneously or sequentially.
The field faces fundamental questions: Should therapies be administered simultaneously to hit multiple targets at once, or sequentially to address disease progression through different stages? How do we select which combinations based on biomarkers? What can we learn from oncology's experience with combination therapies? This gap page addresses these critical questions.
Neurodegenerative diseases are characterized by multiple, interconnected pathological mechanisms:
- Alzheimer's disease: Amyloid-beta plaques, tau tangles, neuroinflammation, synaptic loss, mitochondrial dysfunction
- Parkinson's disease: alpha-synuclein aggregation, dopaminergic neuron loss, neuroinflammation, mitochondrial dysfunction
- ALS: TDP-43 aggregation, SOD1 mutations, excitotoxicity, neuroinflammation
Single-target therapies have shown limited efficacy, leading to increased interest in combination approaches.
Combination therapies can achieve synergy through several mechanisms:
- Complementary target engagement: Different therapies target different pathological pathways
- Sequential pathway modulation: One therapy primes the system for another
- Reduced compensatory mechanisms: Single-target approaches often trigger compensatory pathways that limit efficacy
- Dose reduction: Synergistic effects may allow lower doses of individual agents, reducing side effects
Advantages:
- Immediate multi-target engagement
- Potential for synergistic effects at the same disease stage
- Simplified treatment protocol (single time window)
- May prevent compensatory pathway activation
Challenges:
- Increased risk of drug-drug interactions
- Difficulty determining which component is effective
- Regulatory complexity for combination products
- Higher cost and accessibility barriers
Examples in development:
- Amyloid-targeting + tau-targeting combinations
- Anti-inflammatory + neuroprotective combinations
Advantages:
- Can address disease stage-specific pathology
- Allows assessment of individual therapy efficacy
- May reduce cumulative toxicity
- Enables biomarker-guided progression to next therapy
Challenges:
- Requires reliable biomarkers for stage identification
- May miss critical treatment windows
- Complex long-term management
- Patient adherence over extended timeframes
Research from 2025-2026 has begun to clarify optimal sequencing approaches:
In Alzheimer's disease:
- Amyloid removal (anti-amyloid antibodies) → Tau modulation → Neuroprotection
- Anti-amyloid → Anti-inflammatory → Synaptic support
- Biomarker-guided: amyloid-lowering → tau-targeted → downstream pathway modulators
In Parkinson's disease:
- Alpha-synuclein reduction → Dopamine preservation → Neuroprotection
- Disease-modifying → Symptomatic → Supportive care
- Stage-based: early (disease-modifying) → middle (combinatorial) → late (symptomatic + neuroprotective)
¶ Current Biomarker Landscape
| Biomarker |
Disease |
Application |
| Amyloid PET |
AD |
Patient selection, treatment response |
| CSF p-tau181/217 |
AD |
Tau pathology, treatment monitoring |
| Neurofilament light (NfL) |
AD, PD, ALS |
Disease progression, treatment response |
| Alpha-synuclein RT-QuIC |
PD |
Diagnosis, treatment selection |
| GRN mutation status |
FTD |
Treatment eligibility |
Recent advances in biomarker technology enable more precise treatment selection:
Amyloid-guided selection:
- Patients with high amyloid burden benefit most from anti-amyloid therapy
- Post-amyloid clearance, tau-targeted therapy becomes more relevant
- Combination may be most effective in amyloid-positive, early-stage patients
Tau PET-guided approaches:
- High tau burden may require more aggressive combination approaches
- Tau spread pattern informs choice of tau-targeting agents
Inflammation biomarkers:
- Elevated cytokines may indicate patients who benefit from anti-inflammatory combinations
- Microglial activation markers (TSPO PET) guide immunomodulatory selection
- Dose optimization: Determining optimal doses for each component
- Factorial designs: Testing each component alone and in combination
- Regulatory pathways: FDA and EMA requirements for combination products
- Long-term follow-up: Extended trials needed to assess durability
- Patient heterogeneity: Identifying which patients benefit most
Platform trials: Adaptive platform designs allow efficient testing of multiple combinations
Master protocols: Common control arms and adaptive randomization improve efficiency
Basket trials: Tumor-agnostic approaches adapted for genetically defined neurodegenerative subtypes
Digital twin trials: Using modeling to simulate combination effects
- Primary: Clinical dementia rating (CDR), disease progression rates
- Secondary: Biomarker change (amyloid, tau, NfL), brain volume
- Exploratory: Cognitive composite scores, functional outcomes
Oncology has successfully developed combination therapies that offer lessons for neurodegeneration:
1. Targeted therapy combinations:
- BRAF inhibitors + MEK inhibitors in melanoma
- EGFR inhibitors + chemotherapy in lung cancer
- Lesson: Targeting sequential nodes in a pathway can prevent resistance
2. Immunotherapy combinations:
- Checkpoint inhibitors + chemotherapy
- Multiple immunotherapy agents
- Lesson: Multi-modal immune engagement can be more effective
3. Resistance management:
- Combination approaches to prevent or overcome resistance
- Biomarker-driven selection of combination partners
| Oncology Principle |
Neurodegeneration Application |
| Sequential targeted therapy |
Stage-specific treatment sequencing |
| Combination to prevent resistance |
Multi-target approaches to prevent compensatory pathways |
| Biomarker-driven selection |
Patient stratification for combination choice |
| Adaptive trial designs |
Platform trials for combination testing |
| Minimum effective dose |
Lower doses in combinations to reduce toxicity |
- Different disease biology: Cancer cells divide; neurons are post-mitotic
- Accessibility: Tumors are more accessible than CNS
- Biomarkers: Cancer biomarkers more developed
- Treatment windows: Cancer treated more aggressively
1. Lecanemab and combination approaches:
- Phase 3 Clarity data support early treatment initiation
- Ongoing trials exploring add-on to lecanemab
- Biomarker studies identify optimal patient subgroups
2. Tau targeting combinations:
- Anti-tau antibodies in combination with amyloid removal
- Small molecule tau aggregation inhibitors in development
- Early 2026 results from combination trials expected
3. Neuroprotective combinations:
- NRF2 activators combined with anti-amyloid
- Mitochondrial protectors in combination approaches
- Synaptic plasticity enhancers in development
4. Biomarker advances:
- Plasma p-tau217 approved for patient selection
- Real-world evidence on combination outcomes
- AI-driven biomarker combinations for precision medicine
| Trial |
Phase |
Combination |
Status |
| NCT05XXXXX |
Phase 2 |
Lecanemab + anti-tau |
Recruiting |
| NCT06XXXXX |
Phase 2 |
NRF2 activator + standard care |
Active |
| NCT07XXXXX |
Phase 1 |
Gene therapy + small molecule |
Phase 1 |
Alzheimer's disease:
- Anti-amyloid monotherapy (lecanemab, donanemab)
- Add symptomatic treatments (AChEIs, memantine)
- Future: Combination based on biomarkers
Parkinson's disease:
- Disease-modifying (in development)
- Symptomatic (dopamine agonists, MAO-B inhibitors)
- Future: Combination with neuroprotective agents
Multi-target small molecules:
- Single molecules with multiple mechanisms
- Examples: AChEIs with disease-modifying activity
Gene therapy combinations:
- Multiple genes delivered simultaneously
- Gene therapy + small molecule combinations
Cell therapy combinations:
- Cell replacement + supportive therapies
- Immunomodulation + cell therapy
¶ Knowledge Gaps and Future Directions
- Optimal timing: When in disease course should combinations be initiated?
- Biomarker validation: Which biomarker combinations best predict response?
- Resistance mechanisms: How do neurodegenerative diseases resist combination therapy?
- Long-term effects: What are the long-term outcomes of combination approaches?
- Individual variation: How do genetic factors influence combination response?
- Develop validated biomarker panels for combination selection
- Create predictive models for combination response
- Establish regulatory frameworks for combination therapies
- Design efficient clinical trials for multiple combinations
- Identify mechanisms of synergy in human patients